Pharmacokinetics of Levofloxacin and Capreomycin in Multidrug-Resistant Tuberculosis Patients

Pharmacokinetics of Levofloxacin and Capreomycin in MDR-TB Patients

This is an open label observational pharmacokinetic drug study to evaluate Levofloxacine and Capreomycin in patients with Multidrug-Resistant Tuberculosis (MDR-TB).

Patients receive MDR-TB treatment with o.a. Levofloxacin and Capreomycin. At least one week after start of treatment, the PK samples samples will be obtained via an intravenous catheter at 0, 1, 2, 3, 4, 7, and 12 hours after intake.

Inclusion Criteria:

• age> 18yrs
• culture positive
• diagnosis of MDR-TB

Exclusion Criteria:

• DM2
• Pregnancy
• allergy to IV canula material
• insertion of IV canula not possibele